{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:59:31Z","timestamp":1785517171833,"version":"3.56.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People with HIV (PWH), particularly women, have a high cardiovascular disease (CVD) burden compared to the general population. There is little evidence describing statin adherence among PWH, which could inform interventions to reduce CVD disparities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Observational cohort of privately insured PWH under age 65 who initiated statin therapy during 2015\u20132022 in MarketScan data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Measures<\/jats:title>\n                    <jats:p>We used outpatient pharmacy claims to examine (1) statin discontinuation, defined as a gap\u2009&gt;\u200990 days, and (2) proportion of days covered (PDC) by a statin in 90-day intervals. We estimated hazard ratios (HRs) using Cox models to compare discontinuation rates and prevalence ratios (PRs) from log-binomial regression to compare the probability of having low adherence (PDC\u2009&lt;\u200980%) between women and men. We adjusted for potential confounding by demographic and clinical factors and accounted for repeated PDC measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Results<\/jats:title>\n                    <jats:p>We included 9522 PWH who initiated a statin (median age 52 years, 17.3% women). Overall, 50.0% of PWH had statin discontinuation within 2 years, and 26.5% had low adherence during statin therapy. Within 2 years, 59.0% of women and 48.1% of men had experienced discontinuation (adjusted HR 1.30 (95% CI, 1.20\u20131.41)). Among PWH remaining on statins, low adherence (PDC\u2009&lt;\u200980%) was more common among women (34.1%) than men (25.2%) (adjusted PR 1.29 (1.22\u20131.35)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PWH had high statin discontinuation rates, and a quarter had low adherence. Compared to men, women were both more likely to discontinue and have lower adherence. Efforts are needed to address statin adherence barriers to prevent CVD in PWH, especially in women with HIV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11606-025-10164-x","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:33:54Z","timestamp":1769186034000},"page":"2873-2881","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gender Differences in Statin Discontinuation and Adherence Among Privately Insured People with HIV in the USA"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8505-9268","authenticated-orcid":false,"given":"Thibaut","family":"Davy-Mendez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan C.","family":"Kinlaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Tungate Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Lance","family":"Okeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Floris-Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Eron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy L.","family":"Avery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi M.","family":"Crane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol E.","family":"Golin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Napravnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Ross J.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"10164_CR1","doi-asserted-by":"crossref","unstructured":"Althoff KN, Buchacz K, Hall HI, et al. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med. 2012;157(5):325\u201335.","DOI":"10.7326\/0003-4819-157-5-201209040-00005"},{"issue":"6","key":"10164_CR2","doi-asserted-by":"publisher","first-page":"376","DOI":"10.7326\/M17-2242","volume":"169","author":"RM Nance","year":"2018","unstructured":"RM Nance JAC Delaney JM Simoni 2018 HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study Ann Intern Med. 169 6 376 384","journal-title":"Ann Intern Med."},{"issue":"12","key":"10164_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081355","volume":"8","author":"H Samji","year":"2013","unstructured":"H Samji A Cescon RS Hogg 2013 Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada PLoS One. 8 12 e81355","journal-title":"PLoS One."},{"issue":"6","key":"10164_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.7954","volume":"3","author":"JL Marcus","year":"2020","unstructured":"JL Marcus WA Leyden SE Alexeeff 2020 Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000\u20132016 JAMA Netw Open. 3 6 e207954","journal-title":"JAMA Netw Open."},{"issue":"24","key":"10164_CR5","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1212\/01.wnl.0000437296.97946.73","volume":"81","author":"FJ Mateen","year":"2013","unstructured":"FJ Mateen WS Post N Sacktor 2013 Long-term predictive value of the Framingham Risk Score for Stroke in HIV-positive vs HIV-negative men Neurology. 81 24 2094 2102","journal-title":"Neurology."},{"issue":"11","key":"10164_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018983","volume":"10","author":"S Erqou","year":"2021","unstructured":"S Erqou L Jiang G Choudhary 2021 Age at Diagnosis of Heart Failure in United States Veterans With and Without HIV Infection J Am Heart Assoc. 10 11 e018983","journal-title":"J Am Heart Assoc."},{"issue":"4","key":"10164_CR7","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/cid\/ciu869","volume":"60","author":"KN Althoff","year":"2015","unstructured":"KN Althoff KA McGinnis CM Wyatt 2015 Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults Clin Infect Dis. 60 4 627 638","journal-title":"Clin Infect Dis."},{"issue":"4","key":"10164_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/QAI.0b013e31825c7f24","volume":"60","author":"FC Chow","year":"2012","unstructured":"FC Chow S Regan S Feske 2012 Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system J Acquir Immune Defic Syndr. 60 4 351 358","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"13","key":"10164_CR9","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1097\/QAD.0000000000000352","volume":"28","author":"JL Marcus","year":"2014","unstructured":"JL Marcus WA Leyden CR Chao 2014 HIV infection and incidence of ischemic stroke AIDS. 28 13 1911 1919","journal-title":"AIDS."},{"issue":"5","key":"10164_CR10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/QAI.0000000000001450","volume":"75","author":"DR Drozd","year":"2017","unstructured":"DR Drozd MM Kitahata KN Althoff 2017 Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population J Acquir Immune Defic Syndr. 75 5 568 576","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"1","key":"10164_CR11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013744","volume":"9","author":"RS Rosenson","year":"2020","unstructured":"RS Rosenson D Hubbard KL Monda 2020 Excess Risk for Atherosclerotic Cardiovascular Outcomes Among US Adults With HIV in the Current Era J Am Heart Assoc. 9 1 e013744","journal-title":"J Am Heart Assoc."},{"issue":"8","key":"10164_CR12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamainternmed.2013.3728","volume":"173","author":"MS Freiberg","year":"2013","unstructured":"MS Freiberg CC Chang LH Kuller 2013 HIV infection and the risk of acute myocardial infarction JAMA Intern Med. 173 8 614 622","journal-title":"JAMA Intern Med."},{"issue":"14","key":"10164_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012241","volume":"8","author":"A Alonso","year":"2019","unstructured":"A Alonso AE Barnes JL Guest 2019 HIV Infection and Incidence of Cardiovascular Diseases: An Analysis of a Large Healthcare Database J Am Heart Assoc. 8 14 e012241","journal-title":"J Am Heart Assoc."},{"issue":"7","key":"10164_CR14","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1210\/jc.2006-2190","volume":"92","author":"VA Triant","year":"2007","unstructured":"VA Triant H Lee C Hadigan 2007 Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease J Clin Endocrinol Metab. 92 7 2506 2512","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"10164_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001035","volume":"3","author":"JA Womack","year":"2014","unstructured":"JA Womack CC Chang KA So-Armah 2014 HIV infection and cardiovascular disease in women J Am Heart Assoc. 3 5 e001035","journal-title":"J Am Heart Assoc."},{"issue":"1","key":"10164_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004325","volume":"21","author":"KN Althoff","year":"2024","unstructured":"KN Althoff C Stewart E Humes 2024 The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study PLoS Med. 21 1 e1004325","journal-title":"PLoS Med."},{"issue":"2","key":"10164_CR17","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1161\/CIR.0000000000000695","volume":"140","author":"MJ Feinstein","year":"2019","unstructured":"MJ Feinstein PY Hsue LA Benjamin  2019 Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association Circulation. 140 2 e98 e124","journal-title":"Circulation."},{"issue":"4","key":"10164_CR18","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/S2352-3018(20)30036-9","volume":"7","author":"K So-Armah","year":"2020","unstructured":"K So-Armah LA Benjamin GS Bloomfield  2020 HIV and cardiovascular disease Lancet HIV. 7 4 e279 e293","journal-title":"Lancet HIV."},{"issue":"25","key":"10164_CR19","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"SM Grundy NJ Stone AL Bailey  2019 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines Circulation. 139 25 e1082 e1143","journal-title":"Circulation."},{"issue":"3","key":"10164_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/cid\/ciw289","volume":"63","author":"ME Clement","year":"2016","unstructured":"ME Clement LP Park AM Navar  2016 Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study Clin Infect Dis. 63 3 407 413","journal-title":"Clin Infect Dis."},{"issue":"5","key":"10164_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/QAI.0000000000003083","volume":"91","author":"SB Coburn","year":"2022","unstructured":"SB Coburn R Lang J Zhang  2022 Statins Utilization in Adults With HIV: The Treatment Gap and Predictors of Statin Initiation J Acquir Immune Defic Syndr. 91 5 469 478","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"8","key":"10164_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","volume":"389","author":"SK Grinspoon","year":"2023","unstructured":"SK Grinspoon KV Fitch MV Zanni  2023 Pitavastatin to Prevent Cardiovascular Disease in HIV Infection N Engl J Med. 389 8 687 699","journal-title":"N Engl J Med."},{"key":"10164_CR23","unstructured":"U.S. Department of Health and Human Services (HHS) Panel for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Recommendations for the Use of Statin Therapy as Primary Prevention of Atherosclerotic Cardiovascular Disease in People with HIV. 2024. Accessed August 15, 2024. Available at https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/statin-therapy-people-hiv."},{"issue":"5","key":"10164_CR24","doi-asserted-by":"publisher","first-page":"301","DOI":"10.7326\/0003-4819-150-5-200903030-00006","volume":"150","author":"MJ Silverberg","year":"2009","unstructured":"MJ Silverberg W Leyden L Hurley  2009 Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection Ann Intern Med. 150 5 301 313","journal-title":"Ann Intern Med."},{"key":"10164_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.annepidem.2020.02.005","volume":"44","author":"ME Levy","year":"2020","unstructured":"ME Levy Y Ma M Magnus  2020 Cholesterol-lowering effect of statin therapy in a clinical HIV cohort: an application of double propensity score adjustment Ann Epidemiol. 44 8 15","journal-title":"Ann Epidemiol."},{"issue":"3","key":"10164_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/cid\/ciq111","volume":"52","author":"S Singh","year":"2011","unstructured":"S Singh JH Willig MJ Mugavero  2011 Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients Clin Infect Dis. 52 3 387 395","journal-title":"Clin Infect Dis."},{"key":"10164_CR27","doi-asserted-by":"crossref","unstructured":"Burkholder GA, Muntner P, Zhao H, et al. Low-density lipoprotein cholesterol response after statin initiation among persons living with human immunodeficiency virus. J Clin Lipidol. 2018;12(4):988\u2013998 e5.","DOI":"10.1016\/j.jacl.2018.03.082"},{"issue":"2","key":"10164_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1089\/apc.2017.0304","volume":"32","author":"ME Levy","year":"2018","unstructured":"ME Levy AE Greenberg M Magnus  2018 Evaluation of Statin Eligibility, Prescribing Practices, and Therapeutic Responses Using ATP III, ACC\/AHA, and NLA Dyslipidemia Treatment Guidelines in a Large Urban Cohort of HIV-Infected Outpatients AIDS Patient Care STDS. 32 2 58 69","journal-title":"AIDS Patient Care STDS."},{"issue":"6","key":"10164_CR29","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1089\/aid.2014.0126","volume":"31","author":"AK Monroe","year":"2015","unstructured":"AK Monroe W Fu MN Zikusoka  2015 Low-Density Lipoprotein Cholesterol Levels and Statin Treatment by HIV Status Among Multicenter AIDS Cohort Study Men AIDS Res Hum Retroviruses. 31 6 593 602","journal-title":"AIDS Res Hum Retroviruses."},{"issue":"3","key":"10164_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s11606-008-0891-7","volume":"24","author":"MS Freiberg","year":"2009","unstructured":"MS Freiberg DA Leaf JL Goulet  2009 The association between the receipt of lipid lowering therapy and HIV status among veterans who met NCEP\/ATP III criteria for the receipt of lipid lowering medication J Gen Intern Med. 24 3 334 340","journal-title":"J Gen Intern Med."},{"issue":"7","key":"10164_CR31","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/cid\/ciw448","volume":"63","author":"SG Al-Kindi","year":"2016","unstructured":"SG Al-Kindi DA Zidar GA McComsey  2016 Gender Differences in Statin Prescription Rate Among Patients Living With HIV and Hepatitis C Virus Clin Infect Dis. 63 7 993 994","journal-title":"Clin Infect Dis."},{"issue":"4","key":"10164_CR32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/09540121.2015.1099602","volume":"28","author":"NL Okeke","year":"2016","unstructured":"NL Okeke T Chin M Clement  2016 Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis AIDS Care. 28 4 475 482","journal-title":"AIDS Care."},{"issue":"3","key":"10164_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/hiv.12794","volume":"21","author":"AL Blackman","year":"2020","unstructured":"AL Blackman NS Pandit KJ Pincus 2020 Comparing rates of statin therapy in eligible patients living with HIV versus uninfected patients HIV Med. 21 3 135 141","journal-title":"HIV Med."},{"issue":"4","key":"10164_CR34","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1177\/0897190021999790","volume":"35","author":"RP Emmons","year":"2022","unstructured":"RP Emmons NV Hastain TA Miano  2022 Patients Living With HIV Are Less Likely to Receive Appropriate Statin Therapy for Cardiovascular Disease Risk Reduction J Pharm Pract. 35 4 568 572","journal-title":"J Pharm Pract."},{"key":"10164_CR35","doi-asserted-by":"crossref","unstructured":"Larson D, Won SH, Ganesan A, et al. Statin usage and cardiovascular risk among people living with HIV in the U.S. Military HIV Natural History Study. HIV Med. 2022;23(3):249\u2013258.","DOI":"10.1111\/hiv.13195"},{"issue":"12","key":"10164_CR36","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1258\/095646207782716974","volume":"18","author":"ML Townsend","year":"2007","unstructured":"ML Townsend SB Hollowell J Bhalodia  2007 A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia Int J STD AIDS. 18 12 851 855","journal-title":"Int J STD AIDS."},{"key":"10164_CR37","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijcard.2016.09.075","volume":"225","author":"M Banach","year":"2016","unstructured":"M Banach T Stulc R Dent  2016 Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement Int J Cardiol. 225 184 196","journal-title":"Int J Cardiol."},{"issue":"1","key":"10164_CR38","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010376","volume":"8","author":"LD Colantonio","year":"2019","unstructured":"LD Colantonio RS Rosenson L Deng  2019 Adherence to Statin Therapy Among US Adults Between 2007 and 2014 J Am Heart Assoc. 8 1 e010376","journal-title":"J Am Heart Assoc."},{"issue":"1","key":"10164_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201196","volume":"14","author":"HF Hope","year":"2019","unstructured":"HF Hope GM Binkley S Fenton  2019 Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease PLoS One. 14 1 e0201196","journal-title":"PLoS One."},{"key":"10164_CR40","doi-asserted-by":"crossref","unstructured":"Lewey J, Shrank WH, Bowry AD, et al. Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J. 2013;165(5):665\u201378, 678 e1.","DOI":"10.1016\/j.ahj.2013.02.011"},{"issue":"1","key":"10164_CR41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jacl.2020.11.001","volume":"15","author":"KB Crockett","year":"2021","unstructured":"KB Crockett Y Wen ET Overton  2021 One-year statin persistence and adherence in adults with HIV in the United States J Clin Lipidol. 15 1 181 191","journal-title":"J Clin Lipidol."},{"issue":"8","key":"10164_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25382","volume":"22","author":"B Youn","year":"2019","unstructured":"B Youn TI Shireman Y Lee  2019 Trends in medication adherence in HIV patients in the US, 2001 to 2012: an observational cohort study J Int AIDS Soc. 22 8 e25382","journal-title":"J Int AIDS Soc."},{"issue":"25 Suppl 2","key":"10164_CR43","first-page":"S1","volume":"129","author":"NJ Stone","year":"2014","unstructured":"NJ Stone JG Robinson AH Lichtenstein  2014 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines Circulation. 129 25 Suppl 2 S1 45","journal-title":"Circulation."},{"issue":"9","key":"10164_CR44","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1185\/03007990903126833","volume":"25","author":"S Karve","year":"2009","unstructured":"S Karve MA Cleves M Helm  2009 Good and poor adherence: optimal cut-point for adherence measures using administrative claims data Curr Med Res Opin. 25 9 2303 2310","journal-title":"Curr Med Res Opin."},{"issue":"1","key":"10164_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3851\/IMP2450","volume":"18","author":"K Buchacz","year":"2013","unstructured":"K Buchacz RK Baker FJ Palella Jr  2013 Disparities in prevalence of key chronic diseases by gender and race\/ethnicity among antiretroviral-treated HIV-infected adults in the US Antivir Ther. 18 1 65 75","journal-title":"Antivir Ther."},{"issue":"15","key":"10164_CR46","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1097\/QAD.0000000000002349","volume":"33","author":"FJ Palella","year":"2019","unstructured":"FJ Palella R Hart C Armon  2019 Non-AIDS comorbidity burden differs by sex, race, and insurance type in aging adults in HIV care AIDS. 33 15 2327 2335","journal-title":"AIDS."},{"key":"10164_CR47","unstructured":"Centers for Medicare and Medicaid Services. Chronic Conditions Data Warehouse. 2025. Accessed October 10, 2025. Available at https:\/\/www2.ccwdata.org\/web\/guest\/condition-categories-chronic."},{"issue":"4","key":"10164_CR48","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/cid\/ciac086","volume":"75","author":"J Ma","year":"2022","unstructured":"J Ma RM Nance JAC Delaney  2022 Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort Clin Infect Dis. 75 4 715 718","journal-title":"Clin Infect Dis."},{"issue":"8","key":"10164_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104178","volume":"9","author":"SA Safren","year":"2014","unstructured":"SA Safren KB Biello L Smeaton  2014 Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175\/PEARLS trial PLoS One. 9 8 e104178","journal-title":"PLoS One."},{"key":"10164_CR50","doi-asserted-by":"crossref","unstructured":"Carvalho PP, Barroso SM, Coelho HC, et al. Factors associated with antiretroviral therapy adherence in adults: an integrative review of literature. Cien Saude Colet. 2019;24(7):2543\u20132555. Fatores associados \u00e0 ades\u00e3o \u00e0 Terapia Antirretroviral em adultos: revis\u00e3o integrativa de literatura.","DOI":"10.1590\/1413-81232018247.22312017"},{"issue":"1","key":"10164_CR51","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/infdis\/jis731","volume":"208","author":"JL O'Connor","year":"2013","unstructured":"JL O'Connor EM Gardner SB Mannheimer  2013 Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial J Infect Dis. 208 1 40 49","journal-title":"J Infect Dis."},{"issue":"7","key":"10164_CR52","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s10461-010-9756-2","volume":"15","author":"JA Bianco","year":"2011","unstructured":"JA Bianco TG Heckman M Sutton  2011 Predicting adherence to antiretroviral therapy in HIV-infected older adults: the moderating role of gender AIDS Behav. 15 7 1437 1446","journal-title":"AIDS Behav."},{"issue":"8","key":"10164_CR53","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1097\/QAD.0b013e32833847af","volume":"24","author":"V Cambiano","year":"2010","unstructured":"V Cambiano FC Lampe AJ Rodger  2010 Long-term trends in adherence to antiretroviral therapy from start of HAART AIDS. 24 8 1153 1162","journal-title":"AIDS."},{"key":"10164_CR54","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2147\/PPA.S245365","volume":"14","author":"MV Ingersgaard","year":"2020","unstructured":"MV Ingersgaard T Helms Andersen O Norgaard  2020 Reasons for Nonadherence to Statins - A Systematic Review of Reviews Patient Prefer Adherence. 14 675 691","journal-title":"Patient Prefer Adherence."},{"key":"10164_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/PPA.S502645","volume":"19","author":"J Rosenberg","year":"2025","unstructured":"J Rosenberg S Lampridou A Moores  2025 A Systematic Review Uncovering Modifiable Influences on Statin Adherence Patient Prefer Adherence. 19 29 48","journal-title":"Patient Prefer Adherence."},{"key":"10164_CR56","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2147\/PPA.S254882","volume":"14","author":"C Muiruri","year":"2020","unstructured":"C Muiruri IP Sico J Schexnayder  2020 Why Do People Living with HIV Adhere to Antiretroviral Therapy and Not Comorbid Cardiovascular Disease Medications? A Qualitative Inquiry. Patient Prefer Adherence. 14 985 994","journal-title":"A Qualitative Inquiry. Patient Prefer Adherence."},{"key":"10164_CR57","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1186\/1472-6963-13-488","volume":"13","author":"AK Monroe","year":"2013","unstructured":"AK Monroe TL Rowe RD Moore  2013 Medication adherence in HIV-positive patients with diabetes or hypertension: a focus group study BMC Health Serv Res. 13 488","journal-title":"BMC Health Serv Res."},{"issue":"1","key":"10164_CR58","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12875-024-02370-z","volume":"25","author":"A Ogunbajo","year":"2024","unstructured":"A Ogunbajo I Todd D Zajdman  2024 Statin use for cardiovascular disease prevention: perceptions among people living with HIV in the United States BMC Prim Care. 25 1 116","journal-title":"BMC Prim Care."},{"issue":"10059","key":"10164_CR59","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"R Collins C Reith J Emberson  2016 Interpretation of the evidence for the efficacy and safety of statin therapy Lancet. 388 10059 2532 2561","journal-title":"Lancet."},{"key":"10164_CR60","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists' Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"issue":"8a","key":"10164_CR61","doi-asserted-by":"publisher","first-page":"52c","DOI":"10.1016\/j.amjcard.2005.12.010","volume":"97","author":"M Law","year":"2006","unstructured":"M Law AR Rudnicka 2006 Statin safety: a systematic review Am J Cardiol. 97 8a 52c 60c","journal-title":"Am J Cardiol."},{"issue":"5","key":"10164_CR62","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","volume":"7","author":"MY Wei","year":"2013","unstructured":"MY Wei MK Ito JD Cohen  2013 Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education J Clin Lipidol. 7 5 472 483","journal-title":"J Clin Lipidol."},{"issue":"4","key":"10164_CR63","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacl.2016.02.016","volume":"10","author":"DG Karalis","year":"2016","unstructured":"DG Karalis RA Wild KC Maki  2016 Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study J Clin Lipidol. 10 4 833 841","journal-title":"J Clin Lipidol."},{"key":"10164_CR64","doi-asserted-by":"crossref","unstructured":"van Driel ML, Morledge MD, Ulep R, et al. Interventions to improve adherence to lipid-lowering medication. Cochrane Database Syst Rev. 2016;12(12):CD004371.","DOI":"10.1002\/14651858.CD004371.pub4"},{"key":"10164_CR65","doi-asserted-by":"crossref","unstructured":"Reston JT, Buelt A, Donahue MP, et al. Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease : A Systematic Review for the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Management of Dyslipidemia. Ann Intern Med. 2020;173(10):806\u2013812.","DOI":"10.7326\/M20-4680"},{"issue":"3","key":"10164_CR66","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.56445","volume":"7","author":"CT Longenecker","year":"2024","unstructured":"CT Longenecker KA Jones CO Hileman  2024 Nurse-Led Strategy to Improve Blood Pressure and Cholesterol Level Among People With HIV: A Randomized Clinical Trial JAMA Netw Open. 7 3 e2356445","journal-title":"JAMA Netw Open."},{"issue":"2","key":"10164_CR67","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pcad.2020.02.012","volume":"63","author":"S Takada","year":"2020","unstructured":"S Takada AJ Ober JS Currier  2020 Reducing cardiovascular risk among people living with HIV: Rationale and design of the INcreasing Statin Prescribing in HIV Behavioral Economics REsearch (INSPIRE) randomized controlled trial Prog Cardiovasc Dis. 63 2 109 117","journal-title":"Prog Cardiovasc Dis."},{"issue":"2","key":"10164_CR68","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pcad.2020.03.006","volume":"63","author":"JC Gamble-George","year":"2020","unstructured":"JC Gamble-George CT Longenecker AR Webel  2020 ImPlementation REsearCh to DEvelop Interventions for People Living with HIV (the PRECluDE consortium): Combatting chronic disease comorbidities in HIV populations through implementation research Prog Cardiovasc Dis. 63 2 79 91","journal-title":"Prog Cardiovasc Dis."},{"issue":"8","key":"10164_CR69","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1001\/jama.2022.12138","volume":"328","author":"R Chou","year":"2022","unstructured":"R Chou A Cantor T Dana  2022 Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force JAMA. 328 8 754 771","journal-title":"JAMA."},{"issue":"683","key":"10164_CR70","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.3399\/bjgp19X702701","volume":"69","author":"P Byrne","year":"2019","unstructured":"P Byrne J Cullinan P Gillespie  2019 Statins for primary prevention of cardiovascular disease: modelling guidelines and patient preferences based on an Irish cohort Br J Gen Pract. 69 683 e373 e380","journal-title":"Br J Gen Pract."},{"key":"10164_CR71","doi-asserted-by":"crossref","unstructured":"Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;2013(1):Cd004816.","DOI":"10.1002\/14651858.CD004816.pub5"},{"issue":"11","key":"10164_CR72","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamacardio.2019.3665","volume":"4","author":"MB Mortensen","year":"2019","unstructured":"MB Mortensen BG Nordestgaard 2019 Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat JAMA Cardiol. 4 11 1131 1138","journal-title":"JAMA Cardiol."},{"issue":"2","key":"10164_CR73","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamacardio.2022.4873","volume":"8","author":"C Soares","year":"2023","unstructured":"C Soares M Kwok KA Boucher  2023 Performance of Cardiovascular Risk Prediction Models Among People Living With HIV: A Systematic Review and Meta-analysis JAMA Cardiol. 8 2 139 149","journal-title":"JAMA Cardiol."},{"issue":"10","key":"10164_CR74","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029228","volume":"13","author":"VA Triant","year":"2024","unstructured":"VA Triant A Lyass LB Hurley  2024 Cardiovascular Risk Estimation Is Suboptimal in People With HIV J Am Heart Assoc. 13 10 e029228","journal-title":"J Am Heart Assoc."},{"key":"10164_CR75","unstructured":"Kaiser Family Foundation. Insurance Coverage and Viral Suppression Among People with HIV, 2018. 2020. Accessed April 15, 2024. Available at https:\/\/www.kff.org\/hivaids\/issue-brief\/insurance-coverage-and-viral-suppression-among-people-with-hiv-2018\/."},{"issue":"4","key":"10164_CR76","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s11606-010-1253-9","volume":"25","author":"MA Fischer","year":"2010","unstructured":"MA Fischer MR Stedman J Lii  2010 Primary medication non-adherence: analysis of 195,930 electronic prescriptions J Gen Intern Med. 25 4 284 290","journal-title":"J Gen Intern Med."},{"issue":"6","key":"10164_CR77","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13350","volume":"73","author":"MHH Cheen","year":"2019","unstructured":"MHH Cheen YZ Tan LF Oh 2019 Prevalence of and factors associated with primary medication non-adherence in chronic disease: A systematic review and meta-analysis Int J Clin Pract. 73 6 e13350","journal-title":"Int J Clin Pract."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-10164-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-10164-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-10164-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:04:16Z","timestamp":1785513856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-10164-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":77,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10164"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-10164-x","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was determined to be exempt from review by the Institutional Review Board (IRB) of the University of North Carolina at Chapel Hill (UNC).","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.M.C. reports grants or contracts from ViiV Healthcare; participation on an advisory panel for ViiV Healthcare. J.J.E. reports grants or contracts from ViiV Healthcare; consulting fees from Merck and Gilead Sciences; participation on a DSMB or advisory board for Merck and TIAMED. M.F.-M. reports participation on an advisory board for ViiV Healthcare. A.C.K. reports grants from the Genentech Foundation; honoraria and travel support from the American Diabetes Association to speak at a scientific meeting. N.L.O. reports consulting fees from ViiV Healthcare. R.J.S. reports consulting fees from Merck. All other authors report no conflict of interest.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}